仪器信息网·2025-06-10 08:17Core Viewpoint - The revenue of 14 companies in the life sciences sector shows a "7 increase and 7 decrease" pattern, indicating a recovery trend in the industry as most companies have narrowed their revenue decline compared to 2023 [1][4]. Revenue Performance Summary - In 2024, the revenue of Shunyi Optical reached 38.295 billion yuan, a year-on-year increase of 20.87%, while its optical instrument business saw a decline of 18.4% [3][8]. - Mindray Medical reported a revenue of 36.726 billion yuan, a growth of 5.14%, with its in vitro diagnostics segment achieving a revenue of 13.765 billion yuan, up 10.82% [3][10]. - Antu Bio achieved a revenue of 4.471 billion yuan, a slight increase of 0.62% [3][10]. - The revenue of Tailin Bio was 349 million yuan, marking a significant increase of 29.33%, driven primarily by the pharmaceutical industry [3][7]. Sector-Specific Insights - In the sequencing instrument sector, BGI Genomics achieved a revenue of 3.012 billion yuan, with a notable increase in sales volume of nearly 1,270 units, representing a 48.59% year-on-year growth [4][5]. - The low-temperature storage sector showed signs of stabilization, with Haier Bio's revenue at 2.283 billion yuan, a slight increase of 0.13% [6]. - The optical microscope sector faced challenges, with several companies reporting declines in revenue, including Micron Optics with a revenue of 1.354 billion yuan, down 0.86% [8][9]. Declining Companies - New Zhi Bio reported a revenue of 168 million yuan, a decrease of 11.90%, while BoXun Bio's revenue fell to 122 million yuan, down 14.14% [9]. - Yirui Bio's revenue was 224 million yuan, reflecting a decline of 11.75% [9]. IVD Market Overview - The IVD market in China grew from 43 billion yuan in 2016 to 118.5 billion yuan in 2023, with a compound annual growth rate of 15.58% [10].